Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 28, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 1,450,000 Ordinary shares of 25 pence each.
- Purchase Date: June 28, 2012.
- Price Range: Highest price paid was 1,465.5 pence per share; lowest price paid was 1,436.5 pence per share.
- Treasury Holdings (Settled): 474,357,927 shares (8.68% of total issued share capital).
- Treasury Holdings (Including Unsettled): 478,307,927 shares (9.58% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,993,081,459 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,450,000 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 9.58% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (4,993,081,459) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the settlement status of the 1,450,000 shares purchased on June 28, 2012.
- Review the total Treasury share count (478,307,927) to assess the impact on total voting rights (9.58%).